<i>Slbp</i> mutants have increased DNA damage and exhibit tetraploid nuclei.

<p>Larval neuroblast karyotypes were obtained for <i>Slbp¹⁵</i> and <i>w¹¹¹⁸</i> 3^rd instar larvae. Each karyotype was assigned to one of four categories: I) Normal karyotype with no chromosomal breaks II) Normal karyotype with at least one chromosomal break (arrow), III) Tetraploid with no breaks, IV) Tetraploid with at least one break (arrows). White arrows indicate examples of chromosomal breaks.</p

<i>Slbp</i> mutants are modifiers of PEV.

<p>Eyes were analyzed for extent of variegation in flies carrying one copy of the <i>w^m4</i> inversion with one of the following genotypes: <i>Slbp¹⁵/Slbp¹⁰, Slbp¹⁵/+,</i> and <i>wt</i>. A) Representative eyes from females of each genotype. B) Quantitative assay for PEV. Eye pigment was quantified by measuring absorbance at 480λ for 30 fly heads per sample. C) Absorbance values of samples from allelic combinations of <i>Slbp</i> mutations. For each genotype, n = 10, except when comparing <i>Slbp¹⁵/Slbp¹⁰</i> and <i>Slbp¹⁵/+</i>, for which n = 3. Each pair of bars represents a single experiment. P-values are indicated as follows: * p<0.05, **p<0.01, ***p<0.001. Error bars indicate SEM.</p

<i>Slbp</i> mutants have no detectable global change in histone protein levels.

<p>Protein lysates from <i>wt, Slbp¹⁵, Slbp¹⁰</i>, and <i>H2aV⁸¹⁰</i> mutants were obtained from whole 3^rd instar larvae and probed with antibodies to A) H2b and H3, and B) H3K4-me2 and H3K9-me2. β-tubulin was used as a loading control for both panels.</p

Mean Percentage of Mitotic Nuclei Per Brain in Each Class.

<p>For each genotype, the percentage of nuclei containing chromosomal breaks and tetraploidy was calculated for 6 individual brains and mean percentages determined. 23–132 mitotic nuclei per individual brain were analyzed. Four classes of abnormal karyotypes (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0008168#pone-0008168-g002" target="_blank">Figure 2</a>): I) Normal karyotype with no breaks. II) Diploid nuclei containing breaks. II + IV) All nuclei containing breaks. III) Tetraploid nuclei without breaks. III + IV) Total tetraploid nuclei including those with breaks. IV) Tetraploid nuclei with breaks.</p

LOH is significantly increased in <i>Slbp</i> mutants.

<p>Wings from wt, <i>Slbp¹⁰</i> mutant flies heterozygous for a fourth chromosome translocation containing <i>y⁺</i> were mounted and the first twenty bristles of the anterior wing margin were used for analysis. A) Example of the data used for analysis. Yellow bristles indicate an LOH event (black arrows). B) For each <i>Slbp¹⁰</i> and<i> + </i>class, the frequencies of yellow bristles per wing were compared to heterozygous controls derived from a common culture. Frequency of yellow bristles was tabulated on a per wing basis. Data are expressed as a percentage of heterozygous controls, so that genotypes can be compared across experiments. 21-45 wings were analyzed per class. P-values are indicated as follows: * p<0.05, **p<0.01, ***p<0.001.</p

Overall survival estimates for aggressive non-Hodgkin lymphoma in Lilongwe, Malawi.

<p>Overall survival estimates for aggressive non-Hodgkin lymphoma in Lilongwe, Malawi.</p

Peripheral blood counts with interquartile ranges during CHOP chemotherapy in Lilongwe, Malawi.

<p>Peripheral blood counts with interquartile ranges during CHOP chemotherapy in Lilongwe, Malawi.</p

Risk factors for mortality among aggressive non-Hodgkin lymphoma patients in Lilongwe, Malawi.

<p>Risk factors for mortality among aggressive non-Hodgkin lymphoma patients in Lilongwe, Malawi.</p

Treatment course and toxicities during CHOP chemotherapy in Lilongwe, Malawi.

<p>Treatment course and toxicities during CHOP chemotherapy in Lilongwe, Malawi.</p

Overall survival for aggressive non-Hodgkin lymphoma in Lilongwe, Malawi.

<p>(A) Overall cohort with 95% confidence intervals. (B) Aggressive B-cell non-Hodgkin lymphoma (ABNHL) versus aggressive T-cell non-Hodgkin lymphoma (ATNHL). (C) Stratified by HIV status. (D) Stratified by international prognostic index (IPI). (E) Diffuse large B-cell lymphoma (DLBCL) stratified by HIV status. (F) DBLCL stratified by IPI.</p